Abstract
Introduction: Although the first results from studies suggested important benefits regarding blood pressure (BP) control in resistant hypertension by the use of diverse systems of renal denervation (RDN) in the setting of resistant hypertension, the Symplicity HTN-3, randomized sham-controlled trial reduced the enthusiasm and led to a more critical approach towards this neuromodulation innovative therapy. Nowadays there is an ongoing research attempt to justify the pathophysiological background of RDN since overdrive of the sympathetic nervous system is one of the key mechanisms leading to the development and progression of the hypertensive and cardiovascular diseases.
Conclusion: Future RDN trials based on the clinical findings and gaps from previous works will try to identify those parameters to help identify better BP response, target the most suitable population and conclude whether this interventional approach can contribute to the clinical problem of uncontrolled hypertension.
Keywords: Renal denervation, resistant hypertension, blood pressure response, Symplicity HTN-3, BP, cardiovascular disease.
Graphical Abstract
Current Vascular Pharmacology
Title:Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?
Volume: 16 Issue: 1
Author(s): Costas Tsioufis*, Kyriakos Dimitriadis, Athanasios Kordalis, Michalis Doumas, Dimitris Konstantinidis, Theodoros Kalos, Felix Mahfoud, Vasilios Papademetriou and Dimitrios Tousoulis
Affiliation:
- First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens,Greece
Keywords: Renal denervation, resistant hypertension, blood pressure response, Symplicity HTN-3, BP, cardiovascular disease.
Abstract: Introduction: Although the first results from studies suggested important benefits regarding blood pressure (BP) control in resistant hypertension by the use of diverse systems of renal denervation (RDN) in the setting of resistant hypertension, the Symplicity HTN-3, randomized sham-controlled trial reduced the enthusiasm and led to a more critical approach towards this neuromodulation innovative therapy. Nowadays there is an ongoing research attempt to justify the pathophysiological background of RDN since overdrive of the sympathetic nervous system is one of the key mechanisms leading to the development and progression of the hypertensive and cardiovascular diseases.
Conclusion: Future RDN trials based on the clinical findings and gaps from previous works will try to identify those parameters to help identify better BP response, target the most suitable population and conclude whether this interventional approach can contribute to the clinical problem of uncontrolled hypertension.
Export Options
About this article
Cite this article as:
Tsioufis Costas *, Dimitriadis Kyriakos, Kordalis Athanasios , Doumas Michalis , Konstantinidis Dimitris , Kalos Theodoros, Mahfoud Felix , Papademetriou Vasilios and Tousoulis Dimitrios , Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?, Current Vascular Pharmacology 2018; 16 (1) . https://dx.doi.org/10.2174/1570161115666170426151649
DOI https://dx.doi.org/10.2174/1570161115666170426151649 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoxins, The Novel Mediators of Gastroprotection and Gastric Adaptation to Ulcerogenic action of Aspirin
Current Pharmaceutical Design The Importance of Lost Minerals in Heart Failure
Cardiovascular & Hematological Agents in Medicinal Chemistry Obesity- An Adverse Factor in Reproductive Age
Applied Clinical Research, Clinical Trials and Regulatory Affairs Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Potential of Statins for Individualized Colorectal Cancer Chemoprevention
Current Drug Targets Regulators of Platelet cAMP Levels: Clinical and Therapeutic Implications
Current Medicinal Chemistry Editorial (Hot Topic: New Insights into Insulin Resistance, Cardiovascular Diseases and Oxidative Stress: Pathophysiological and Clinical Consequences)
Current Pharmaceutical Design Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
CNS & Neurological Disorders - Drug Targets Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Complications of the Type 2 Diabetes Mellitus
Current Cardiology Reviews The Renin-Angiotensin System: Emerging Concepts
Current Hypertension Reviews Antioxidative Actions of Statins: Potential Mechanisms for Antiathersclerotic Effects
Mini-Reviews in Medicinal Chemistry T-Cells and B-Cells in Systemic Sclerosis
Current Rheumatology Reviews Pathophysiology of Thrombosis and Potential Targeted Therapies in Antiphospholipid Syndrome
Current Vascular Pharmacology Heart Transplantation in Biventricular Congenital Heart Disease: Indications, Techniques, and Outcomes
Current Cardiology Reviews Editorial [Hot Topic: Oxidative Stress Induced-Metabolic Imbalance, Mitochondrial Failure, And Cellular Hypoperfusion As Primary Pathogenetic Factors For The Development Of Alzheimer Disease Which Can Be Used As An Alternate And Successful Drug Treatment Strategy: Past, Present And Future (Guest Editor: Gjumrakch Aliev)]
CNS & Neurological Disorders - Drug Targets Docking Studies for Multi-Target Drugs
Current Drug Targets Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Uteroplacental Circulation and Fetal Vascular Function and Development
Current Vascular Pharmacology Carbon Monoxide - Toxicity of Low-Dose Application
Current Pharmaceutical Biotechnology